Johnson & Johnson (NYSE:JNJ) is Richard C. Young & CO. LTD.’s 6th Largest Position

Richard C. Young & CO. LTD. cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 113,633 shares of the company’s stock after selling 252 shares during the period. Johnson & Johnson accounts for about 2.7% of Richard C. Young & CO. LTD.’s portfolio, making the stock its 6th largest position. Richard C. Young & CO. LTD.’s holdings in Johnson & Johnson were worth $20,073,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Confluence Wealth Services Inc. increased its stake in Johnson & Johnson by 3.1% in the 4th quarter. Confluence Wealth Services Inc. now owns 26,419 shares of the company’s stock valued at $4,667,000 after purchasing an additional 798 shares in the last quarter. Banque Cantonale Vaudoise raised its stake in shares of Johnson & Johnson by 6.4% during the 4th quarter. Banque Cantonale Vaudoise now owns 171,388 shares of the company’s stock worth $30,277,000 after buying an additional 10,376 shares during the last quarter. Aviva PLC boosted its position in shares of Johnson & Johnson by 19.8% in the 4th quarter. Aviva PLC now owns 984,585 shares of the company’s stock worth $13,007,000 after buying an additional 162,472 shares in the last quarter. Beacon Harbor Wealth Advisors Inc. purchased a new position in Johnson & Johnson during the 4th quarter valued at about $509,000. Finally, Associated Banc Corp raised its position in Johnson & Johnson by 0.8% during the fourth quarter. Associated Banc Corp now owns 180,324 shares of the company’s stock worth $31,854,000 after acquiring an additional 1,379 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $154.41 on Friday. The company has a market cap of $401.27 billion, a price-to-earnings ratio of 32.30, a price-to-earnings-growth ratio of 2.67 and a beta of 0.53. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $183.35. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The stock’s 50-day moving average is $159.89 and its 200-day moving average is $165.86.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. During the same period in the previous year, the company posted $2.67 earnings per share. Johnson & Johnson’s revenue was up 5.6% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date is Monday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is currently 99.58%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Piper Sandler dropped their price target on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Guggenheim initiated coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective on the stock. Raymond James cut their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. Finally, StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.